Zebrafish for drug toxicity screening: Bridging the in vitro cell-based models and in vivo mammalian models

National University of Singapore, Department of Biological Sciences, Singapore.
Expert Opinion on Drug Metabolism &amp Toxicology (Impact Factor: 2.83). 02/2011; 7(5):579-89. DOI: 10.1517/17425255.2011.562197
Source: PubMed


INTRODUCTION: Over the past decade, zebrafish have been tasked to play important roles from modeling human diseases to finding cures for them. Inadvertently, these fish now find themselves swimming along the drug development pipeline. A number of studies have been conducted to see if these small fish are up to the task of drug toxicity testing, an important rite of passage along the pharmaceutical pipeline. AREAS COVERED: This review covers the recent publications (2008 - 2010) on the state-of-the-art applications that couple advanced technologies with the unique advantages of zebrafish for drug toxicity screening. The paper looks at the several automated high-throughput platforms that have been developed for zebrafish teratogenicity, cardiotoxicity and neuro-sensory organ toxicity assays over the past 3 years as well as the important studies related to metabolism and biotransformation of selected drugs that have been initiated. This paper also reviews their mechanistic and predictive omics applications. EXPERT OPINION: While there have been a number of developments over the past 3 years and indeed over the last 10 years, challenges and limitations still exist, which, unless overcome, will prevent zebrafish from truly reaching their full potential as a drug toxicological model. That being said, recent developments have suggested that zebrafish could play a role in bridging the gap between in vitro cell-based models and in vivo mammalian models.

Download full-text


Available from: Zhiyuan Gong, Nov 19, 2015
  • Source
    • "This could be due to the differences in GR binding activities, pharmacodynamics and/or pharmacokinetics of the different synthetic glucocorticoids in zebrafish compared to mammals/humans. Species differences in pharmacokinetics and pharmacodynamics are common (Toutain et al., 2010) and differences in potency and response to drugs between zebrafish and human have been reported (Redfern et al., 2008; Sukardi et al., 2011). This may suggest that chemically monitoring environmental samples for glucocorticoids that are more potent in fish than in human would have more biological or even ecological relevance. "
    [Show abstract] [Hide abstract]
    ABSTRACT: Glucocorticoids are pharmaceutical contaminants of emerging concern due to their incomplete removal during wastewater treatment, increased presence in aquatic environment and their biological potency. The zebrafish is a popular model for aquatic toxicology and environmental risk assessment. This study aimed to determine if glucocorticoids at environmental concentrations would perturb expression of selected glucocorticoid-responsive genes in zebrafish and to investigate their potentials as an in vivo zebrafish assay in complementing in vitro glucocorticoid receptor bioassay. The relative expression of eleven glucocorticoid-responsive genes in zebrafish larvae and liver of adult male zebrafish exposed to three representative glucocorticoids (dexamethasone, prednisolone and triamcinolone) was determined. The expression of pepck, baiap2 and pxr was up-regulated in zebrafish larvae and the expression of baiap2, pxr and mmp-2 was up-regulated in adult zebrafish exposed to glucocorticoids at concentrations equivalent to total glucocorticoids reported in environmental samples. The responsiveness of the specific genes were sufficiently robust in zebrafish larvae exposed to a complex environmental sample detected with in vitro glucocorticoid activity equivalent to 478 pM dexamethasone (DEX-EQ) and confirmed to contain low concentration (0.2 ng/L or less) of the targeted glucocorticoids, and possibly other glucocorticoid-active compounds. The findings provided in vivo relevance to the in vitro glucocorticoid activity and suggested that the environmental sample can perturb glucocorticoid-responsive genes in its original, or half the diluted, concentration as may be found in the environment. The study demonstrated the important complementary roles of in vivo zebrafish and in vitro bioassays coupled with analytical chemistry in monitoring environmental glucocorticoid contaminants.
    Chemosphere 10/2015; 144:1162-1169. DOI:10.1016/j.chemosphere.2015.09.089 · 3.34 Impact Factor
  • Source
    • "An alternative approach is the use of the whole liver system of zebrafish larvae, with unique advantages for early medium throughput in vivo toxicity screening that can precede preclinical toxicity testing. Zebrafish larvae are only 1–4 mm long and can live in a single well of a 96-well plate for several days (Sukardi et al., 2011). "
    [Show abstract] [Hide abstract]
    ABSTRACT: Drug-induced liver injury (DILI) is poorly predicted by single-cell-based assays, probably because of the lack of physiological interactions with other cells within the liver. An intact whole liver system such as one present in zebrafish larvae could provide added value in a screening strategy for DILI; however, the possible occurrence of other organ toxicities and the immature larval stage of the zebrafish might complicate accurate and fast analysis. We investigated whether expression analysis of liver-specific fatty acid binding protein 10a (lfabp10a) was an appropriate endpoint for assessing hepatotoxic effects in zebrafish larvae. It was found that expression analysis of lfabp10a was a valid marker, as after treatment with hepatotoxicants, dose-response curves could be obtained and statistically significant abnormal lfabp10 expression levels correlated with hepatocellular histopathological changes in the liver. However, toxicity in other vital organs such as the heart could impact liver outgrowth and thus had to be assessed concurrently. Whether zebrafish larvae were suitable for assessing human relevant drug-induced hepatotoxicity was assessed with hepatotoxicants and non-hepatotoxicants that have been marketed for human use and classified according to their mechanism of toxicity. The zebrafish larva showed promising predictivity towards a number of mechanisms and was capable of distinguishing between hepatotoxic and non-hepatotoxic chemical analogues, thus implying its applicability as a potential screening model for DILI. Copyright © 2015 John Wiley & Sons, Ltd. Copyright © 2015 John Wiley & Sons, Ltd.
    Journal of Applied Toxicology 02/2015; 35(9). DOI:10.1002/jat.3091 · 2.98 Impact Factor
  • Source
    • "These studies, while sporadic in nature, underscored a neglected understanding of the ADME profile of drugs between zebrafish and human or other mammalian models which is affected by factors such as the route of administration and physiology of the fish. To fully realize the potential of zebrafish as a drug toxicological model, the knowledge gap in ADME needs to be addressed (Sukardi et al., 2011). Recently, the intra-peritoneal route of administration was used for optimization of the zebrafish model for cardiovascular safety assessment (Chaudhari et al., 2013). "
    [Show abstract] [Hide abstract]
    ABSTRACT: Early assessment of the toxicity potential of new molecules in pharmaceutical industry is a multi-dimensional task involving predictive systems and screening approaches to aid in the optimization of lead compounds prior to their entry into development phase. Due to the high attrition rate in the pharma industry in last few years, it has become imperative for the nonclinical toxicologist to focus on novel approaches which could be helpful for early screening of drug candidates. The need is that the toxicologists should change their classical approach to a more investigative approach. This review discusses the developments that allow toxicologists to anticipate safety problems and plan ways to address them earlier than ever before. This includes progress in the field of in vitro models, surrogate models, molecular toxicology, 'omics' technologies, translational safety biomarkers, stem-cell based assays and preclinical imaging. The traditional boundaries between teams focusing on efficacy/ safety and preclinical/ clinical aspects in the pharma industry are disappearing, and translational research-centric organizations with a focused vision of bringing drugs forward safely and rapidly are emerging. Today's toxicologist should collaborate with medicinal chemists, pharmacologists, and clinicians and these value-adding contributions will change traditional toxicologists from side-effect identifiers to drug development enablers. Copyright © 2013 John Wiley & Sons, Ltd.
    Journal of Applied Toxicology 06/2014; 34(6):576-94. DOI:10.1002/jat.2935 · 2.98 Impact Factor
Show more